Acoustic Pharma-Informatics System

• US 20080020037A1
• Filed: 07/11/2007
• Published: 01/24/2008
• Est. Priority Date: 07/11/2006
• Status: Abandoned Application

• Current Assignee: Proteus Digital Health, Inc. (Otsuka Holdings Company Limited)
• Original Assignee: Proteus Digital Health, Inc. (Otsuka Holdings Company Limited)
• Inventors: Robertson, Timothy, Zdeblick, Mark
• Application Number:
  US11/776,480
• Publication Number:
  US 20080020037A1
• Time in Patent Office: Days
• US Class Current: 424/465
• CPC Class Codes: A61B 5/076 Permanent implantations telemetry using implanted circuitry A61B5/0031; implanted stimulators for therapy A61N1/3605, A61N1/362, A61N1/372
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61B 7/00 Instruments for auscultation
• CPC Class Codes: A61K 49/00 Preparations for testing in vivo
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Compositions, systems and methods that allow for the detection of the actual physical delivery of a pharmaceutical agent to a body are provided. Embodiments of the compositions include an acoustic identifier and an active agent. The invention finds use in a variety of different applications, including but not limited to, monitoring of therapeutic regimen compliance, tracking the history of pharmaceutical agents, etc.

Claims

1. A pharmaceutical composition comprising:

(a) a pharmaceutical active agent;

(b) an acoustic identifier that emits an acoustic signal when it contacts a target site; and

(c) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition according to claim 1, wherein said acoustic identifier comprises a mechanical device that produces said acoustic signal.

3. The pharmaceutical composition according to claim 2, wherein said mechanical device comprises one or more cavities.

4. The pharmaceutical composition according to claim 2, wherein said mechanical device comprises one or more microspheres.

5. The pharmaceutical composition according to claim 2, wherein said mechanical device comprises a whistle.

6. The pharmaceutical composition according to claim 2, wherein mechanical device comprises a wafer having a textured surface and a striker configured to move across said textured surface in a manner sufficient to produce said acoustic signal.

7. The pharmaceutical composition according to claim 2, wherein said mechanical device comprises an oscillator.

8. The pharmaceutical composition according to claim 2, wherein said physical device comprises a cantilever.

9. The pharmaceutical composition according to claim 2, wherein said identifier further comprises an electronic circuit.

10. The pharmaceutical composition according to claim 2, wherein said identifier does not comprise an electronic component.

11. The pharmaceutical composition according to claim 2, wherein said acoustic pressure signal is an acoustic pressure signature.

12. The pharmaceutical composition according to claim 11, wherein said acoustic pressure signature is a unique signature.

13. The pharmaceutical composition according to claim 11, wherein said acoustic pressure signature is a coded signal.

14. The pharmaceutical composition according to claim 1, wherein said identifier is activated upon contact with a target site fluid present at a target site.

15. The pharmaceutical composition according to claim 14, wherein target site is a stomach.

16. The composition according to claim 1, wherein said composition is an oral formulation.

17. The composition according to claim 16, wherein said oral formulation is a solid oral formulation.

18. A system comprising:

(a) a pharmaceutical composition comprising;

(i) a pharmaceutical active agent;

(ii) an identifier that emits an acoustic signal when it contacts a target site; and

(iii) a pharmaceutically acceptable carrier; and

(b) a receiver for detecting an acoustic signal produced by said identifier.

19. The system according to claim 18, wherein said receiver is an in vivo receiver.

20. The system according claim 18, wherein said receiver is an ex vivo receiver.

21. A method comprising:

administering to a subject an effective amount of an active agent for a condition, wherein said active agent is administered as a pharmaceutical composition comprising;

(a) a pharmaceutical active agent;

(b) an acoustic identifier that emits an acoustic signal when it contacts a target site; and

(c) a pharmaceutically acceptable carrier.

22. The method according to claim 21, wherein said condition is a cardiovascular disease condition.

23. A kit comprising:

two or more pharmaceutical compositions, wherein each of said pharmaceutical compositions comprises;

(i) a pharmaceutical active agent;

(ii) an acoustic identifier that emits an acoustic signal when it contacts a target site; and

(iii) a pharmaceutically acceptable carrier.